WindMIL Therapeutics of Baltimore closed a $32.5 million B financing led by the USarm of China’s Qiming Venture Partners. WindMIL is developing a process to extract and expand bone-marrow memory T-cells, called Marrow-Infiltrating Lymphocytes (MILs™), for cancer immunotherapy. The company is currently conducting a Phase IIb clinical trial in patients with multiple myeloma. Qiming is a tech-healthcare venture capital firm that raised $1.4 billion for three funds earlier this year.
Source: China Biotoday
